Invitrogen™ SuperScript™ IV First-Strand Synthesis System Non-distribution product as customer accommodation.

Optimized for synthesis of first-strand cDNA from purified poly(A)+ or total RNA.

Manufacturer: Invitrogen™ 18091050

 View more versions of this product

Catalog No. 18-091-050

  Check Availability
Add to Cart

    Specifications

    Includes Oligo(dT)20 (50 µM), 50 µL; Random hexamers (50 ng/µL), 250 µL; 5X RT buffer, 1 mL 0.1 M DTT, 250 µL; 10 mM dNTP mix, 250 µL SuperScript® IV RT (10,000 units total at 200 U/µl), 50 µL; RNaseOUT™ (40 U/µL), 100 µL; E. coli RNase H (2 U/µL), 50 µL; DEPC-treated water, 1.2 mL; Total HeLa RNA (10 ng/µL), 20 µL; Sense Control Primer (10 µM), 25 µL; Antisense Control Primer (10 µM), 25 µL
    Quantity 50 reactions
    Size (Final Product) 12.3 kb or less
    Storage Requirements All components stored at -5 to -30°C.

    Optimized for synthesis of first-strand cDNA from purified poly(A)+ or total RNA.

    The kit includes SuperScript™ IV Reverse Transcriptase (RT), a proprietary MMLV mutant that produces robust and reliable cDNA synthesis in RT reactions. The SuperScript IV synthesis system is significantly improved over the SuperScript III-based system in inhibitor resistance, processivity, and reaction speed, while retaining all the benefits of the previous system, including increased thermostability, highly efficient full-length cDNA synthesis, and reduced RNase activity. The SuperScript IV system is designed to provide reliable, consistent, and fast cDNA synthesis in the presence of inhibitors found in a wide variety of samples that cause other currently available RTs to perform inefficiently.

    The SuperScript IV First-Strand Synthesis System contains all components needed for RT reactions, plus an additional control gene and primers, and provides the flexibility to customize the RT set-up to fit the needs of your application. The SuperScript IV synthesis system is the top choice for performance and flexibility for RT-PCR applications. We recommend it for all RT-PCR applications, especially when reproducibility and reliability is the primary concern and when inhibitors in the RNA sample may interfere with cDNA synthesis, leading to biases in gene expression studies.

    Features of the SuperScript IV First-Strand Synthesis System include:

    • Significantly improved resistance to a variety of inhibitors that can interfere with cDNA synthesis
    • Robust and specific cDNA synthesis in a wide range of sample types
    • A faster reverse transcriptase reaction that reduces incubation time from >50 min to 10 min
    • Significantly better processivity compared to SuperScript III RT

    Enzyme source
    Purified from E. coli expressing the pol gene of M-MLV, modified to increase thermostability and half-life, processivity, inhibitor resistance and to reduce RNase H activity.

    Performance and quality testing
    Endodeoxyribonuclease, exodeoxyribonuclease, and ribonuclease assays; and yield and length of cDNA product.

    Unit definition
    One unit of SuperScript IV RT is the amount of enzyme required to incorporate 1 nmole of deoxyribonucleotide into acid-precipitable material in 10 min at 37°C using poly(A) oligo(dT)12-18 as a template/primer.

    Unit reaction conditions
    50 mM Tris-HCl (pH 8.3), 4 mM MgCl2, 10 mM DTT, 50 mM KCl, 0.5 mM dTTP, 0.4 MBq/mL [3H]-dTTP, 0.4 mM poly(A) oligo (dT)12-18 and enzyme in 20 µL for 10 min at 37°C.

  • Description & Specifications

Related Products


Product Content Feedback

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit